Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Chiesi-Global-Rare-Diseases"

3 News Found

FDA okays JUXTAPID for kids with ultra-rare genetic cholesterol disorder
News | March 06, 2026

FDA okays JUXTAPID for kids with ultra-rare genetic cholesterol disorder

Chiesi inks agreement with AbbVie subsidiary to push next-generation brain-targeting therapies for rare diseases
News | November 19, 2025

Chiesi inks agreement with AbbVie subsidiary to push next-generation brain-targeting therapies for rare diseases

Chiesi Farmaceutici completes acquisition of Amryt Pharma
News | April 15, 2023

Chiesi Farmaceutici completes acquisition of Amryt Pharma

Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.

Latest Stories

Roche’s Gazyva shows breakthrough results in Lupus phase III trial

Lonza to set up Global Capability Centre in Hyderabad

Merck delivers resilient 2025 performance despite global headwinds

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging